Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This random, open, control and multicenter clinical trial mainly aims to assess the urine
protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy
(IMN).
Phase:
N/A
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine